CoChat

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

Open access

Published version of a preprint

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.

Abstract

B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19 + B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− naïve subset from 35% to over 80% of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modified sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70%. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor- EGFP cassette, which yielded site-specific integration frequencies up to 25%. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics.

Overview

CoChat Summary

TL;DR

This paper reports optimized CRISPR/Cas9 genome engineering of primary human B cells using CD40L/IL4 expansion, electroporation of RNPs or Cas9 mRNA, and AAV6 donor delivery. It achieves >70% CD19 knockout and site-specific AAVS1 integration reported up to 25%, with results peaking at 18 ± 4% at MOI 250,000.

Key findings

  • CD19+ B cells expanded in culture, with the IgD+ IgM+ CD27− naïve subset increasing from 35 ± 6% to 81 ± 2% by day 7 and remaining over 80%; total B cells expanded 10-fold.
  • B cells became permissive to mRNA electroporation by day 3, peaking at day 7; naïve B cell EGFP transfection was 41 ± 8% on day 3, 58 ± 9% on day 7, and 52 ± 7% on day 10.
  • Chemically modified sgRNA with Cas9 protein or Cas9 mRNA induced >70% CD19 indel formation (74 ± 19% and 72 ± 4%) and >70% CD19 protein loss (75 ± 11% and 72 ± 13%); Alt-R gRNA with Cas9 protein gave 65 ± 9% indels and 72 ± 11% CD19 knockout, while Alt-R gRNA with Cas9 mRNA gave no editing. RNP-treated cells showed better post-editing expansion (529,000 ± 150,000 cells, 75 ± 4% viability) than Cas9 mRNA-treated cells (130,000 ± 111,000 cells, 59 ± 18% viability).
  • AAV6 delivered a splice acceptor-EGFP donor to AAVS1, yielding EGFP expression at all MOIs tested and peaking at 18 ± 4% with MOI 250,000; the abstract and discussion report site-specific integration up to 25%. RNPs targeting MYC and IGH created individual DSBs at 78.0% and 56.6%, and the t(8;14) translocation was detected only when both RNPs were combined.

Methods

  • Primary human PBMCs from de-identified healthy donors were obtained by leukapheresis; CD19+ B cells were isolated by immunomagnetic negative selection and expanded with CD40L multimer and IL4.
  • Electroporation used the Neon Transfection System at 1400 V, 10 ms, 3 pulses; CRISPR formats included chemically modified sgRNA or Alt-R crRNA:tracrRNA with Cas9 protein or Cas9 mRNA. Editing was measured by TIDE and flow cytometry.
  • AAV6 was used to deliver a splice acceptor-EGFP cassette with 500 bp homology arms to the AAVS1 safe harbor site; integration was assessed by EGFP expression and junction PCR. Statistical analysis used one-way ANOVA with p < 0.05.

Limitations

  • The paper does not include a formal limitations section. It states that further work is required to fully realize therapeutic potential and that initial t(8;14) cultures showed no obvious transformed properties, with transformation to be studied in greater depth.
  • Evident from the text: no in vivo engraftment, plasma cell maturation, antibody secretion, or therapeutic efficacy data are shown; these are discussed only as future applications.
  • Evident from the text: no off-target analysis is reported, sample sizes are small (n = 2–6 in figures), and the AAVS1 integration efficiency varies between the reported peak of 18 ± 4% in results and “up to 25%” in the abstract/discussion.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41598-018-30358-0

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 B cells are efficiently expanded with CD40L and IL4. Total cell numbers (A) and viability (B) of isolated B cells in culture and during expansion (n = 3). (C) Percentage of Naïve B cells (IgD+ IgM+ CD27−, blue line), Pro or Pre B cells (IgD+ IgM− CD27−, red line), Natural Effector B cells (IgD+ IgM+ CD27+, green line), Memory B cells (IgD− CD27+ CXCR5+, orange line), and Activated Memory B cells (IgD− CD27+ CXCR5−, purple line) of total live CD19+ B cells in culture over time. (n = 3).
Figure 1 B cells are efficiently expanded with CD40L and IL4. Total cell numbers (A) and viability (B) of isolated B cells in culture and during expansion (n = 3). (C) Percentage of Naïve B cells (IgD+ IgM+ CD27−, blue line), Pro or Pre B cells (IgD+ IgM− CD27−, red line), Natural Effector B cells (IgD+ IgM+ CD27+, green line), Memory B cells (IgD− CD27+ CXCR5+, orange line), and Activated Memory B cells (IgD− CD27+ CXCR5−, purple line) of total live CD19+ B cells in culture over time. (n = 3).CC BY · PubMed Central
Figure 2 Electroporation conditions affect B cell transfection efficiency, viability, and post transduction expansion. (A) Table of electroporation conditions tested. (B) The percentage of B cells transfected with chemically modified EGFP coding mRNA (upper panel) as well as post transfection cell viability (middle panel) and expansion (lower panel) (n = 2). Dashed lines indicate pre-electroporation viability and cell count.
Figure 2 Electroporation conditions affect B cell transfection efficiency, viability, and post transduction expansion. (A) Table of electroporation conditions tested. (B) The percentage of B cells transfected with chemically modified EGFP coding mRNA (upper panel) as well as post transfection cell viability (middle panel) and expansion (lower panel) (n = 2). Dashed lines indicate pre-electroporation viability and cell count.CC BY · PubMed Central
Figure 3 B cells become permissive to electroporation in culture. Frequency of EGFP+ cells 2 days after electroporation with mRNA encoding EGFP (left panel) at the indicated time points (n = 6).
Figure 3 B cells become permissive to electroporation in culture. Frequency of EGFP+ cells 2 days after electroporation with mRNA encoding EGFP (left panel) at the indicated time points (n = 6).CC BY · PubMed Central
Figure 4 B cells are efficiently edited by CRISPR/Cas9. (A) B cells were enriched and isolated, electroporated with either chemically modified sgRNA or Alt-R gRNA in combination with either Cas9 protein or chemically modified mRNA encoding Cas9 protein, and then assessed for indel formation (n = 6). (B) Frequency of indel formation as measured by TIDE analysis (left panel) and loss of CD19 expression as measured by flow cytometry (right panel), viability (left panel) and total cell numbers (right panel) (*indicate p < 0.05) (n = 6).
Figure 4 B cells are efficiently edited by CRISPR/Cas9. (A) B cells were enriched and isolated, electroporated with either chemically modified sgRNA or Alt-R gRNA in combination with either Cas9 protein or chemically modified mRNA encoding Cas9 protein, and then assessed for indel formation (n = 6). (B) Frequency of indel formation as measured by TIDE analysis (left panel) and loss of CD19 expression as measured by flow cytometry (right panel), viability (left panel) and total cell numbers (right panel) (*indicate p < 0.05) (n = 6).CC BY · PubMed Central
Figure 5 Simultaneous application of RNPs targeting MYC and IGH creates a t(8; 14) Burkitt Lymphoma translocation. (A) Diagram of relative positions of MYC on Chromosome 8 (left diagram), the IGH locus on Chromosome 14 (center diagram) and the t(8; 14) translocation (right diagram) associated with Burkitt Lymphoma. Arrows indicate primer direction and triangles indicate gRNA target sites. (B) Indel pattern and efficiency of RNPs targeting MYC (top panel) and IGH (bottom panel). (C) PCR amplification using MYC (left panel), IGH locus (middle panel), or a combination of MYC/IGH locus primers (right panel) of samples engineered with RNPs targeting MYC, the IGH locus, or a combination of MYC and IGH locus, as well as no gRNA (represented by ‘–’) and H2O controls.
Figure 5 Simultaneous application of RNPs targeting MYC and IGH creates a t(8; 14) Burkitt Lymphoma translocation. (A) Diagram of relative positions of MYC on Chromosome 8 (left diagram), the IGH locus on Chromosome 14 (center diagram) and the t(8; 14) translocation (right diagram) associated with Burkitt Lymphoma. Arrows indicate primer direction and triangles indicate gRNA target sites. (B) Indel pattern and efficiency of RNPs targeting MYC (top panel) and IGH (bottom panel). (C) PCR amplification using MYC (left panel), IGH locus (middle panel), or a combination of MYC/IGH locus primers (right panel) of samples engineered with RNPs targeting MYC, the IGH locus, or a combination of MYC and IGH locus, as well as no gRNA (represented by ‘–’) and H2O controls.CC BY · PubMed Central
Figure 6 B cells can be engineered using homologous recombination with rAAV6 donor and CRISPR/Cas9. (A) A schematic design of the DNA donor template for a splice acceptor-EGFP system targeting the AAVS1 site by HR used in this study. (B) Percentage of EGFP+ cells represent integration frequency following transfection with rAAV6 containing a splice acceptor-EGFP system at the indicated MOIs (n = 3). (C) PCR amplification using a combination of EGFP and AAVS1 primers of samples engineered with RNPs targeting AAVS1 and exposed to rAAV6 containing a splice acceptor-EGFP system at the indicated MOIs, as well as no gRNA (represented by ‘–’) and H2O controls.
Figure 6 B cells can be engineered using homologous recombination with rAAV6 donor and CRISPR/Cas9. (A) A schematic design of the DNA donor template for a splice acceptor-EGFP system targeting the AAVS1 site by HR used in this study. (B) Percentage of EGFP+ cells represent integration frequency following transfection with rAAV6 containing a splice acceptor-EGFP system at the indicated MOIs (n = 3). (C) PCR amplification using a combination of EGFP and AAVS1 primers of samples engineered with RNPs targeting AAVS1 and exposed to rAAV6 containing a splice acceptor-EGFP system at the indicated MOIs, as well as no gRNA (represented by ‘–’) and H2O controls.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 11 Not checked · 36 Own results and interpretations

26 more claims

Create a free account to see all 47 claims and to verify the 19 references still open.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 93

Metadata

Authors
Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S.
Affiliations
University of Minnesota (US)
Corresponding author
Moriarity, Branden S.
Venue
Scientific Reports
Published
2018-08-14
Volume
8
Issue
1
Pages
12144-12144
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2950101654
Cited by
92
References
41
Citations by year
2026: 9 · 2025: 5 · 2024: 15 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 12 · 2019: 10
FWCI
2.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Cancer Institute (P30CA077598)
  • National Institute of Allergy and Infectious Diseases (R21AI128087)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
CRISPR/Cas9 genome editing, electroporation, B cell expansion, naive B cells, AAVS1 safe harbor, AAV6, site-specific integration, Cas9, antibody production, gene therapy
MeSH terms
RNA, Guide, CRISPR-Cas Systems, B-Lymphocytes, Cells, Cultured, Endonucleases, Genetic Engineering, Humans, Electroporation, Antigens, CD19, Gene Knockout Techniques, Cell Engineering, Primary Cell Culture, CRISPR-Cas Systems, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. https://app.cochat.ai/papers/10.1038/s41598-018-30358-0
The paper
Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S. (2018). Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Scientific Reports. https://doi.org/10.1038/s41598-018-30358-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.